Advertisement
Joseph W. Kaufmann, Kensey Nash's President & CEO, will deliver theCompany's presentation, beginning at approximately 7:55 a.m. (PT). Thepresentation materials will be available on the company's website(http://www.kenseynash.com) beginning at 7:55 a.m. (PT) on Tuesday,September 25, 2007 and will remain on the website for approximately two weeks.
Advertisement
About Kensey Nash Corporation. Kensey Nash Corporation is a leadingmedical technology company providing innovative solutions and technologies fora wide range of medical procedures. The Company provides an extensive rangeof products into multiple medical markets, primarily in the endovascular,sports medicine and spine markets. Many of the products are based on theCompany's significant expertise in the design, development, manufacturing andprocessing of absorbable biomaterials, which has led to partnerships tocommercialize technologies. Kensey Nash has also commercialized a series ofinnovative products through its own direct endovascular sales force. TheCompany is known as a pioneer in the field of arterial puncture closure, asthe inventor and developer of the Angio-Seal(TM) Vascular Closure Device,which is licensed to St. Jude Medical, Inc.
Cautionary Note for Forward-Looking Statements. This press releasecontains forward-looking statements that reflect the Company's currentexpectations about its prospects and opportunities including the Company'sforecast of operating results for the first quarter and fiscal 2008. TheCompany has tried to identify these forward looking statements by using wordssuch as "expect," "anticipate," "estimate," "plan," "will," "forecast,""believe," "guidance," "projection" or similar expressions, but these wordsare not the exclusive means for identifying such statements. The Companycautions that a number of risks, uncertainties, and other important factorscould cause the Company's actual results to differ materially from those inthe forward-looking statements including, without limitation, the Company'ssuccess in launching its endovascular products into the marketplace, theCompany's dependence on three major customers (St. Jude Medical, Arthrex andOrthovita) and their success in selling KNC related products in themarketplace, the impact of product recalls and other manufacturing issues, andcompetition from other technologies, among other important risks. For a moredetailed discussion of these and other factors, please see the Company's SECfilings, including the disclosure under "Risk Factors" in those filings.Except as expressly required by the federal securities laws, the Companyundertakes no obligation to update or revise any forward-looking statements,whether as a result of new information, changed circumstances or future eventsor for any other reason.
SOURCE Kensey Nash Corporation
